Table 1.

Characteristics of six cases of Guillain-Barre syndrome (GBS) after coronavirus disease 2019 (COVID-19)

Patient number	Age (year)/sex	Neurological symptoms and signs	Need for intubation	Electrodiagnostic findings	Treatent	Outcome
1	64/F	Progressive symmetric ascending quadriparesis, areflexia, loss of ambulation	No	Day 25 of symptom onset: axonal motor polyradiculoneuropathy	0.4 g/kg/day IVIg for 5 days	Discharged with significant improvement
2	38/M	Paresthesia and progressive muscle weakness involving upper and lower limbs, bifacial weakness, areflexia, loss of ambulation	Yes	Day 21 of symptom onset: demyelinating sensorimotor polyneuropathy	Plasma exchange for five sessions	Discharged with significant improvement
3	48/F	Asymmetric (right > left) quadriparesis, areflexia, loss of position, and light touch sensation in distal lower limbs	No	Day 32 of symptom onset, day 2 of admission: asymmetric axonal sensorimotor polyradiculoneuropathy	0.4 g/kg/day IVIg for 5 days	Discharged with significant improvement
4	85/F	Progressive symmetric ascending quadriparesis and paresthesia, areflexia, loss of ambulation	No	Day 30 of symptom onset, day 7 of admission: axonal sensorimotor polyradiculoneuropathy	Plasma exchange for five sessions	Discharged with some improvement
5	58/M	Ataxia and distal lower limbs paresthesia, mild foot dorsiflexion weakness, areflexia, glove and stocking sensory loss, abnormal position, and vibration senses	No	Day 11 of symptom onset, day 4 of admission: demyelinating sensorimotor polyneuropathy	0.4 g/kg/day IVIg for 5 days	Discharged with significant improvement
6	43/F	Asymmetric weakness in both legs and then left upper limbs, areflexia in lower limbs, glove and stocking sensory loss, abnormal position, and vibration senses	No	Day 8 of symptom onset, day 5 of admission: axonal motor polyradiculoneuropathy	Plasma exchange for five sessions	Discharged with partial improvement

IVIg: Intravenous immunoglobulin